

CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE  
CONTROVERSIES & UPDATES IN VASCULAR SURGERY

**JANUARY 19-21 2017**

MARRIOTT RIVE GAUCHE & CONFERENCE CENTER

**PARIS, FRANCE**



# Antithrombotic therapy: a critical reading of ACCP guidelines

MA Sevestre, Amiens



## Disclosure

Speaker name: Sevestre MA

.....

- I have the following potential conflicts of interest to report:
- Consulting for Bayer SA, BMS Pfizer, Leo Pharma, Aspen
- Employment in industry
- Shareholder in a healthcare company
- Owner of a healthcare company
- Other(s)
- I do not have any potential conflict of interest



<p><b>Niveau 1</b></p> <ul style="list-style-type: none"><li>• Essais comparatifs randomisés de forte puissance.</li><li>• Méta-analyse d'essais comparatifs randomisés.</li><li>• Analyse de décision basée sur des études bien menées.</li></ul>	<p><b>A</b></p> <p>Preuve scientifique établie.</p>
<p><b>Niveau 2</b></p> <ul style="list-style-type: none"><li>• Essais comparatifs randomisés de faible puissance.</li><li>• Études comparatives non randomisées bien menées.</li><li>• Études de cohorte.</li></ul>	<p><b>B</b></p> <p>Présomption scientifique.</p>
<p><b>Niveau 3</b></p> <ul style="list-style-type: none"><li>• Études cas-témoins.</li></ul>	<p><b>C</b></p> <p>Faible niveau de preuve.</p>
<p><b>Niveau 4</b></p> <ul style="list-style-type: none"><li>• Études comparatives comportant des biais importants.</li></ul>	




# Anything new between 2012 and 2016 ?

- 9 updates and 3 new subjects

**\*2. In patients with DVT of the leg or PE and no cancer, as long-term (first 3 months) anticoagulant therapy, we suggest dabigatran, rivaroxaban, apixaban, or edoxaban over vitamin K antagonist (VKA) therapy (all Grade 2B).**




# Non inferiority studies, 2B



**RIVAROXABAN**

**AMPLIFY**

**APIXABAN**



**EDOXABAN**



**17. In patients with acute DVT or PE who are treated with anticoagulants, we recommend against the use of an inferior vena cava (IVC) filter (Grade 1B).**

**\*18. In patients with acute DVT of the leg, we suggest not using compression stockings routinely to prevent PTS (Grade 2B).**



# Filter the filters

## Research

### Original Investigation


# Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism A Randomized Clinical Trial

Patrick Mismetti, MD, PhD; Silvy Laporte, MS, PhD; Olivier Pellerin, MD, MSc; Pierre-Vladimir Ennezat, MD, PhD; Francis Couturaud, MD, PhD; Antoine Elias, MD, PhD; Nicolas Falvo, MD; Nicolas Meneveau, MD, PhD; Isabelle Quere, MD, PhD; Pierre-Marie Roy, MD, PhD; Olivier Sanchez, MD, PhD; Jeannot Schmidt, MD, PhD; Christophe Seinturier, MD; Marie-Antoinette Sevestre, MD; Jean-Paul Beregi, MD, PhD; Bernard Tardy, MD, PhD; Philippe Lacroix, MD; Emilie Presles, MSc; Alain Leizorovicz, MD; Hervé Decousus, MD; Fabrice-Guy Barral, MD; Guy Meyer, MD; for the PREPIC2 Study Group

*JAMA*. 2015;313(16):1627-1635.



# PTS prevention: pulling your socks (Sox) up!








# Unprovoked VTE: don't stop me now

**9. In patients with a first VTE that is an unprovoked proximal DVT of the leg or PE and who have a (i) low or moderate bleeding risk (see text), we suggest extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 2B), and (ii) high bleeding risk (see text), we recommend 3 months of anticoagulant therapy over extended therapy (no scheduled stop date) (Grade 1B).**


# Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

## The PADIS-PE Randomized Clinical Trial

JAMA. 2015;314(1):31-40.




No. at risk	0	6	12	18	24	30	36	42
Placebo	187	170	162	158	155	141	117	105
Warfarin	184	182	180	174	168	150	120	110



No. at risk	0	6	12	18	24	30	36	42
Placebo	187	185	183	182	181	170	148	130
Warfarin	184	182	180	177	176	162	138	126



- SVT : 2B ?
- DVT diagnosis: what a mess!
- Aspirin in VTE prevention: modest risk reduction



# Antithrombotic Therapy for VTE Disease

## CHEST Guideline and Expert Panel Report

